Illumina, Inc. (NASDAQ:ILMN) Receives Average Recommendation of "Moderate Buy" from Analysts

Illumina, Inc. (NASDAQ:ILMN - Get Free Report) has received a consensus rating of "Moderate Buy" from the twenty-four ratings firms that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, eight have issued a hold recommendation, thirteen have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $162.18.

Several brokerages have commented on ILMN. Canaccord Genuity Group raised their price target on shares of Illumina from $130.00 to $145.00 and gave the company a "hold" rating in a research report on Tuesday. UBS Group lifted their price objective on Illumina from $133.00 to $145.00 and gave the company a "neutral" rating in a research note on Tuesday. Hsbc Global Res raised shares of Illumina from a "hold" rating to a "strong-buy" rating and set a $180.00 target price on the stock in a report on Thursday, October 17th. HSBC upgraded shares of Illumina from a "hold" rating to a "buy" rating and set a $180.00 price target for the company in a report on Thursday, October 17th. Finally, Citigroup raised their price objective on shares of Illumina from $155.00 to $190.00 and gave the company a "buy" rating in a report on Tuesday.

Institutional Trading of Illumina

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Envestnet Portfolio Solutions Inc. raised its stake in shares of Illumina by 426.0% during the first quarter. Envestnet Portfolio Solutions Inc. now owns 15,460 shares of the life sciences company's stock worth $2,123,000 after purchasing an additional 12,521 shares during the last quarter. Jupiter Asset Management Ltd. purchased a new position in Illumina during the 1st quarter worth $4,527,000. US Bancorp DE lifted its stake in shares of Illumina by 33.9% in the 1st quarter. US Bancorp DE now owns 31,600 shares of the life sciences company's stock worth $4,339,000 after acquiring an additional 8,001 shares during the period. Cetera Advisors LLC purchased a new stake in shares of Illumina in the first quarter valued at about $610,000. Finally, Weybosset Research & Management LLC boosted its holdings in shares of Illumina by 92.0% in the third quarter. Weybosset Research & Management LLC now owns 18,052 shares of the life sciences company's stock valued at $2,354,000 after acquiring an additional 8,650 shares in the last quarter. 89.42% of the stock is owned by hedge funds and other institutional investors.

Illumina Trading Down 2.0 %

Shares of NASDAQ ILMN traded down $3.13 during trading on Wednesday, reaching $151.83. The stock had a trading volume of 2,815,785 shares, compared to its average volume of 2,007,547. The company has a debt-to-equity ratio of 1.04, a quick ratio of 0.86 and a current ratio of 1.11. The company has a market cap of $24.19 billion, a P/E ratio of -15.56 and a beta of 1.13. Illumina has a fifty-two week low of $89.00 and a fifty-two week high of $156.66. The business's 50-day moving average price is $136.87 and its 200-day moving average price is $122.92.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.88 by $0.26. Illumina had a negative net margin of 68.73% and a positive return on equity of 3.08%. The company had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.08 billion. During the same period in the prior year, the firm earned $0.33 earnings per share. The business's revenue for the quarter was down 3.5% compared to the same quarter last year. On average, equities research analysts predict that Illumina will post 3.62 EPS for the current fiscal year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.